| Nano-sized titanium dioxide-induced splenic toxicity: A biological pathway explored using microarray technology L Sheng, L Wang, X Sang, X Zhao, J Hong, S Cheng, X Yu, D Liu, B Xu, ... Journal of Hazardous Materials 278, 180-188, 2014 | 57 | 2014 |
| Engineered mesenchymal stem cells for targeting solid tumors: therapeutic potential beyond regenerative therapy S Cheng, SK Nethi, S Rathi, B Layek, S Prabha Journal of Pharmacology and Experimental Therapeutics 370 (2), 231-241, 2019 | 56 | 2019 |
| The full-length cytochrome P450 enzyme CYP102A1 dimerizes at its reductase domains and has flexible heme domains for efficient catalysis H Zhang, AL Yokom, S Cheng, M Su, PF Hollenberg, DR Southworth, ... Journal of Biological Chemistry 293 (20), 7727-7736, 2018 | 44 | 2018 |
| Phoxim‐induced damages of Bombyx mori larval midgut and titanium dioxide nanoparticles protective role under phoxim‐induced toxicity J Su, B Li, S Cheng, Z Zhu, X Sang, S Gui, Y Xie, Q Sun, Z Cheng, ... Environmental toxicology 29 (12), 1355-1366, 2014 | 35 | 2014 |
| Pharmacokinetic—pharmacodynamic modeling of tumor targeted drug delivery using nano-engineered mesenchymal stem cells S Cheng, SK Nethi, M Al-Kofahi, S Prabha Pharmaceutics 13 (1), 92, 2021 | 11 | 2021 |
| Pharmacokinetic Modeling of Warfarin І–Model-Based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals CYP2C9 Genotype-Dependent Drug-Drug … S Cheng, DR Flora, AE Rettie, RC Brundage, TS Tracy Drug Metabolism and Disposition 50 (9), 1287-1301, 2022 | 8 | 2022 |
| Pharmacokinetic Modeling of Warfarin ІI–Model-Based Analysis of Warfarin Metabolites after Warfarin Administered Either Alone or Together with Fluconazole or Rifampin S Cheng, DR Flora, AE Rettie, RC Brundage, TS Tracy Drug Metabolism and Disposition 50 (9), 1302-1311, 2022 | 5 | 2022 |
| A physiological-based pharmacokinetic model embedded with a target-mediated drug disposition mechanism can characterize single-dose warfarin pharmacokinetic profiles in … S Cheng, DR Flora, AE Rettie, RC Brundage, TS Tracy Drug Metabolism and Disposition 51 (2), 257-267, 2023 | 3 | 2023 |
| PBPK Model Development, Validation, and Application for Prediction of Eliglustat Drug‐Drug Interactions SA Sahasrabudhe, S Cheng, M Al‐Kofahi, JR Jarnes, NJ Weinreb, ... Clinical Pharmacology & Therapeutics, 2022 | 2* | 2022 |
| Evaluation of bias in weighted residual calculations when handling below the limit of quantification data using Beal’s M3 method MM Jaber, S Cheng, RC Brundage CPT: Pharmacometrics & Systems Pharmacology 10 (4), 275, 2021 | 2 | 2021 |
| Amphipol-facilitated elucidation of the functional tetrameric complex of full-length cytochrome P450 CYP2B4 and NADPH-cytochrome P450 oxidoreductase S Cheng, Z Bo, P Hollenberg, Y Osawa, H Zhang Journal of Biological Chemistry 296, 2021 | 2 | 2021 |
| Population Pharmacokinetic Analysis of Atomoxetine and its Metabolites in Children and Adolescents with Attention‐Deficit/Hyperactivity Disorder S Cheng, M Al‐Kofahi, JS Leeder, JT Brown Clinical Pharmacology & Therapeutics 115 (5), 1033-1043, 2024 | | 2024 |
| POPULATION PHARMACOKINETICS OF ATOMOXETINE AND ITS METABOLITES IN CHILDREN AND ADOLESCENTS WITH ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD). M Al-Kofahi, S Cheng, S Leeder, J Brown CLINICAL PHARMACOLOGY & THERAPEUTICS 111, S10-S10, 2022 | | 2022 |
| Understanding the Impact of Pharmacogenetic Differences in Drug-Drug Interactions (DDIs): a Model-based Approach to Predict Differences in Drug Exposure S Cheng University of Minnesota, 2021 | | 2021 |
| Model-based analysis of the CYP2C9 genotype impact on the fluconazole inhibition of the commonly prescribed drugs flurbiprofen, ketoprofen, and tolbutamide S Cheng, MM Jaber, DR Flora, TS Tracy, AE Rettie, RC Brundage 2021 American College of Clinical Pharmacology, 2021 | | 2021 |
| Genotype-Dependent Changes in Warfarin Clearance upon Co-administration of an Inhibitor (fluconazole) and an inducer (rifampin): A Model-based Analysis S Cheng, DR Flora, TS Tracy, AE Rettie, RC Brundage American Conference on Pharmacometrics 11 (ACoP11) 2 (ISSN:2688-3953), WED-071, 2020 | | 2020 |
| Synthetic antigen receptor mesenchymal stem cells (SAR-MSCs) targeting perlecan for drug delivery to ovarian cancer SK Nethi, D Sehgal, S Cheng, J Panyam, S Prabha Cancer Research 79 (13_Supplement), 2175-2175, 2019 | | 2019 |
| Elucidating the Disposition of Nano-engineered Mesenchymal Stem Cells using Pharmacokinetic Modeling S Cheng, B Layek, M Al-Kofahi, RC Brundage, S Prabha American Conference on Pharmacometrics 10 (ACoP10) 1 (ISSN:2688-3953), T-042, 2019 | | 2019 |
Susheel Kumar Nethi, Ph.D.Nanovaccine Institute, Iowa State UniversityVerified email at iastate.edu
